Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions

被引:41
作者
Abdelrahim, Mohamed E. [1 ,2 ]
机构
[1] Univ Beni Suef, Fac Pharm, Dept Clin Pharm, Bani Suwayf, Egypt
[2] Univ Tours, Fac Med, Tours, France
关键词
Terbutaline sulphate; Turbuhaler; Dose emission; Urine samples; Inhalation twice; DRY POWDER INHALERS; OBSTRUCTIVE PULMONARY-DISEASE; FLOW-RATE; DELIVERY CHARACTERISTICS; DRUG-DELIVERY; INHALATION; SALBUTAMOL; BUDESONIDE; FORMOTEROL; EFFICACY;
D O I
10.1016/j.rmed.2009.11.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Turbuhaler has a very high resistance hence patient inhalation flow when using it would be low. The total emitted dose (TED) of 500 mu g terbutaline sulphate from a Bricanyl Turbuhaler was determined using a range of inhalation flows (10-60 L min(-1)) with inhalation volume of 2 and 4 L using a DPI sampling apparatus after one and two inhalations. The relative lung and systemic bioavailability of terbutaline from Bricanyl Turbuhaler when used by healthy subjects and COPD patients were determined after one and two inhalations at slow and fast inhalation flows using a novel urinary terbutaline pharmacokinetic method. The TED resulted from the one and two inhalations increased significantly (p < 0.05) with the increase of the inhalation flow at both 2 and 4 L inhalation volumes. The relative lung and systemic bioavailability after one inhalation at fast inhalation flow were significantly higher (p < 0.01) than at slow inhalation flow in both healthy subjects and patients. Also the healthy subjects results were significantly higher (p < 0.05) than the COPD patients after one inhalation. However after two inhalations there was no significant difference between slow and fast inhalation flow or healthy subjects and COPD patients. Hence it is essential to inhale twice and as deep and hard as possible from each dose of Turbuhaler for patients with low inspiratory flow and limited inhalation volume as they may not receive much benefit from one inhalation. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:682 / 689
页数:8
相关论文
共 31 条
[11]   Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease [J].
Cazzola, M ;
D'Amato, M ;
Califano, C ;
Di Perna, F ;
Calderaro, F ;
Matera, MG ;
D'Amato, G .
CLINICAL THERAPEUTICS, 2002, 24 (04) :595-604
[12]   Is inhalation rate important for a dry powder inhaler? using the In-Check Dial to identify these rates [J].
Chrystyn, H .
RESPIRATORY MEDICINE, 2003, 97 (02) :181-187
[13]   THE RELATIONSHIP BETWEEN POWDER INHALER RESISTANCE AND PEAK INSPIRATORY CONDITIONS IN HEALTHY-VOLUNTEERS - IMPLICATIONS FOR IN-VITRO TESTING [J].
CLARK, AR ;
HOLLINGWORTH, AM .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1993, 6 (02) :99-110
[14]   Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers .2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers [J].
deBoer, AH ;
Gjaltema, D ;
Hagedoorn, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 138 (01) :45-56
[15]   Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD [J].
Derom, Eric ;
Strandgarden, Kerstin ;
Schelfhout, Vanessa ;
Borgstrom, Lars ;
Pauwels, Romain .
RESPIRATORY MEDICINE, 2007, 101 (09) :1931-1941
[16]   Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy [J].
Hawksworth, GM ;
James, L ;
Chrystyn, H .
RESPIRATORY MEDICINE, 2000, 94 (05) :501-504
[17]   A comparison of the performance of two modern multidose dry powder asthma inhalers [J].
Hill, LS ;
Slater, AL .
RESPIRATORY MEDICINE, 1998, 92 (01) :105-110
[18]   DETERMINATION OF THE RELATIVE BIOAVAILABILITY OF SALBUTAMOL TO THE LUNG FOLLOWING INHALATION [J].
HINDLE, M ;
CHRYSTYN, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (04) :311-315
[19]   SIMULATED IN-USE AND MIS-USE ASPECTS OF THE DELIVERY OF TERBUTALINE SULFATE FROM BRICANYL TURBOHALER(TM) DRY POWDER INHALERS [J].
MEAKIN, BJ ;
CAINEY, JM ;
WOODCOCK, PM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 119 (01) :103-108
[20]   DRUG-DELIVERY CHARACTERISTICS OF BRICANYL TURBOHALER(TM) DRY POWDER INHALERS [J].
MEAKIN, BJ ;
CAINEY, JM ;
WOODCOCK, PM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 119 (01) :91-102